Medtronic ’s Redemption Arc for RDN Continues at EuroPCR

Redemption of Medtronic’s renal denervation program to treat hypertension is seemingly on the horizon. The Dublin-based company reported results from an investigator-led study and a registry that demonstrate long-term results of RDN’s impact on uncontrolled hypertension. These results were presented during a Late-Breaking Clinical Trial session at EuroPCR in Paris. In the investigator -led study data indicated RDN with the Medtronic Symplicity system was associated with reduced occurrence of subclinical Atrial Fibrillation (AFib) in a small subset of high-risk patients with hypertensive heart disease over a median follow-up period of more than two years. The study randomized 80 patients to either the RDN procedure with the Symplicity system or a fake "sham" procedure. Results from the study demonstrate subclinical AFib developed at a lower rate in the group of patients who received RDN than those receiving the sham procedure (19% vs. 47%). Three-year data from the Global SYMPLICITY Registry (GSR), which is the largest registry documenting the long-term safety and effectiveness of the Medtronic RDN systems in a real-world setting in patients with uncontrolled hypertension. To date, the registry has enrolled more than 2,600 patients treated with RDN and includes three-year follow-up for more than 2,300 patients. The latest outcomes from the Registry presented at EuroPCR showed RDN led to significant and clinically meaningful reductions in bot...
Source: MDDI - Category: Medical Devices Authors: Tags: Cardiovascular Business Source Type: news